Potassium Channel Blockers
"Potassium Channel Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS.
| Descriptor ID |
D026902
|
| MeSH Number(s) |
D27.505.519.562.500 D27.505.954.411.645
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Potassium Channel Blockers".
Below are MeSH descriptors whose meaning is more specific than "Potassium Channel Blockers".
This graph shows the total number of publications written about "Potassium Channel Blockers" by people in this website by year, and whether "Potassium Channel Blockers" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 1 | 4 |
| 2002 | 2 | 0 | 2 |
| 2003 | 3 | 2 | 5 |
| 2004 | 3 | 1 | 4 |
| 2005 | 2 | 4 | 6 |
| 2006 | 1 | 4 | 5 |
| 2007 | 0 | 5 | 5 |
| 2008 | 1 | 4 | 5 |
| 2009 | 2 | 1 | 3 |
| 2010 | 0 | 3 | 3 |
| 2011 | 3 | 1 | 4 |
| 2012 | 4 | 4 | 8 |
| 2013 | 1 | 2 | 3 |
| 2014 | 2 | 4 | 6 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Potassium Channel Blockers" by people in Profiles.
-
A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis. Proc Natl Acad Sci U S A. 2023 01 10; 120(2):e2211977120.
-
Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia. Muscle Nerve. 2019 09; 60(3):292-298.
-
Active membrane conductances and morphology of a collision detection neuron broaden its impedance profile and improve discrimination of input synchrony. J Neurophysiol. 2019 08 01; 122(2):691-706.
-
Deletion of KCNQ2/3 potassium channels from PV+ interneurons leads to homeostatic potentiation of excitatory transmission. Elife. 2018 11 01; 7.
-
Somatostatin Is Only Partly Required for the Glucagonostatic Effect of Glucose but Is Necessary for the Glucagonostatic Effect of KATP Channel Blockers. Diabetes. 2018 11; 67(11):2239-2253.
-
Targeting KCa1.1 Channels with a Scorpion Venom Peptide for the Therapy of Rat Models of Rheumatoid Arthritis. J Pharmacol Exp Ther. 2018 05; 365(2):227-236.
-
Revealing kinetics and state-dependent binding properties of IKur-targeting drugs that maximize atrial fibrillation selectivity. Chaos. 2017 Sep; 27(9):093918.
-
Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats. Sci Rep. 2017 06 16; 7(1):3756.
-
Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog. Clin Immunol. 2017 07; 180:45-57.
-
99mTc Sestamibi Thyroid Scan in Amiodarone-Induced Thyrotoxicosis Type I. Clin Nucl Med. 2016 Jul; 41(7):566-7.